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BACKGROUND: Preclinical investigations support combining sorafenib with IL-2 in the treatment of metastatic renal cell carcinoma
(mRCC).
METHODS: In this open-label, phase II study, 128 patients with mRCC were randomised to receive oral sorafenib, 400mg twice daily,
plus subcutaneous IL-2, 4.5 million international units (MIU) five times per week for 6 in every 8 weeks, or sorafenib alone. After
enrolment of the first 40 patients, IL-2 dose was reduced to improve the tolerability.
RESULTS: After a median follow-up of 27 months, median progression-free survival (PFS) was 33 weeks with sorafenib plus IL-2, and 30
weeks with sorafenib alone (P¼0.109). For patients receiving the initial higher dose of IL-2, median PFS was 43 weeks vs 31 weeks
for those receiving the lower dose. The most common adverse events were asthenia, hand–foot syndrome, hypertension, and
diarrhoea. Grade 3–4 adverse events were reported for 38 and 25% of patients receiving combination and single-agent treatment,
respectively.
CONCLUSION: The combination of sorafenib and IL-2 did not demonstrate improved efficacy vs sorafenib alone. Improvements in PFS
appeared greater in patients receiving higher-dose IL-2.
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For the past two decades, immunotherapy has been the only
therapeutic approach to demonstrate a moderate, but unequivocal
benefit in a restricted patient population with clear-cell renal cell
carcinoma (Yang et al, 2003; McDermott et al, 2005). Indeed, after
the cloning of the genes encoding interleukin (IL)-2 and
interferon-alpha (IFN-a), extensive clinical investigations under-
taken in metastatic renal cell carcinoma (mRCC) showed that these
biological agents yielded response rates ranging from 8 to 26%
with only modest effects on the natural history of the disease in
terms of overall survival (OS) (McDermott and Atkins, 2008). In a
phase II non-randomised trial, Fisher et al (2000) reported long-
term complete remissions with high doses of IL-2 administered
intravenously, thus suggesting that the efficacy of IL-2 might
correlate with doses and administration methods.
The multikinase inhibitor (TKI) sorafenib (Nexavar; Bayer
HealthCare, Milan, Italy), which targets the Raf/MEK/ERK pathway
as well as vascular endothelial growth factor receptors (VEGFRs) 1,
2 and 3, platelet-derived growth factor receptor (PDGFR)-b, c-Kit,
Fit-3 and RET, has shown dual anti-proliferative and anti-
angiogenic activity (Wilhelm et al, 2004). A pivotal, randomised,
placebo-controlled, phase III clinical trial (the TARGET study)
(Escudier et al, 2007a) demonstrated a significant improvement in
progression-free survival (PFS) with sorafenib (5.5 months) vs
placebo (2.8 months; Po0.001) in patients with clear-cell mRCC
refractory or intolerant to cytokines. Following this trial, the drug
was the first targeted therapy to be approved by the US Food
and Drug Administration for the treatment of this disease.
A subsequent randomised phase two trial comparing sorafenib
with IFN-a as first-line treatment in mRCC demonstrated no
differences in terms of PFS in the two arms of therapy (5.7 vs 5.6
months, P¼0.50) (Escudier et al, 2009).
Preclinical investigations have provided evidence to support the
combination of sorafenib with IL-2 (Iguchi et al, 2009; Amagai
et al, 2010). IL-2 acts to induce the proliferation and activation of
T cells, B cells, natural killer (NK)-cells and lymphokine-activated
killer cells, resulting in multiple biological effects including the
proliferation of antigen-stimulated T cells and the induction of
cytotoxicity through the activation of tumouricidal monocytes.
This led to the hypothesis that the different mechanisms of action
of sorafenib and IL-2 on T-cell signalling and proliferation could
be synergistic, and provide improved clinical outcomes in patients
with mRCC.
On the basis of these assumptions, this randomised, prospective,
phase II, clinical study compared the combination of sorafenib
plus IL-2 vs sorafenib alone in patients with mRCC not previously
treated with systemic therapy.
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Patients
Eligible patients were aged 18 years or older, with a life expectancy
of at least 3 months, and an Eastern Cooperative Oncology Group
(ECOG) performance status of two or less. They were required to
have a histologically confirmed diagnosis of advanced or meta-
static RCC, all histologies, with at least one measurable unidimen-
sional lesion detected by computed tomography (CT) or magnetic
resonance imaging (MRI) scan and evaluated according to
Response Evaluation Criteria for Solid Tumours (RECIST) criteria
version 1.0 (Therasse et al, 2000). In cases of initial diagnosis of
RCC dating back more than 2 years, cytohistological confirmation
of RCC origin of the current lesions was mandatory. Eligible
patients had not been previously treated with systemic therapy for
metastatic disease, but patients could have undergone previous
nephrectomy. The following baseline haematochemical values were
considered mandatory for eligibility: absolute neutrophil count
X1.5 10
9l
 1; platelet count X100 10
9l
 1; haemoglobin
49gdl
 1; serum creatinine p2.0  the upper limit of normal
(ULN); total bilirubin o1.5 ULN; aspartate aminotransferase
(AST) or alanine aminotransferase (ALT) o2.5 ULN for patients
without liver metastases and o5 ULN for patients with liver
metastases; amylase and lipase o1.5 ULN. Exclusion criteria
included a history of brain metastases, presence of concomitant
illnesses, or medical conditions, such as serious respiratory or
cardiovascular diseases, unstable angina, uncontrolled hyperten-
sion (X160mmHg systolic and/or 90mmHg diastolic pressure),
unstable diabetes mellitus, serious bacterial or fungal infections, or
potentially life-threatening autoimmune disorders. Patients with
other previous malignancies were considered ineligible, with the
exception of those with a history of adequately treated basal- or
squamous-cell skin cancer or in situ cervical cancer.
Study design
This was a prospective, randomised, open-label, multicentre,
phase II study designed to evaluate the efficacy and safety of the
combination of sorafenib plus IL-2 vs sorafenib alone in previously
untreated patients with unresectable or metastatic RCC. The
primary endpoint of the study was PFS, and the secondary
endpoints included objective response rate (ORR), OS, and the
safety profile of the two therapeutic regimens.
Patients were randomly allocated (1:1) to treatment with either
oral sorafenib 400mg (2 200mg tablets) twice daily for the entire
study period combined with IL-2 administered subcutaneously at a
dose of 4.5 million international units (MIU) on 5 days per week
for 6 weeks with treatment repeated every 8 weeks, or with
sorafenib alone at the same dose as above. However, after
treatment of the first 40 patients, of whom 20 were randomised
to the combination treatment arm, the protocol was amended to
reduce the dose of IL-2–3 MIU 5 days per week, 2 weeks on and 2
weeks off, because of the onset of AEs. Patients received study
treatment until tumour progression, symptomatic deterioration, or
onset of unacceptable toxicity requiring drug discontinuation and
withdrawal of the patient from the study.
The study design was approved by the Ethical Committees of
each Institution and was performed in accordance with the
Declaration of Helsinki and Good Clinical Practice guidelines. At
enrolment, each patient gave written informed consent. Rando-
misation was performed centrally at the Italian Trials in Medical
Oncology (ITMO) office. To ensure balance between the treatment
arms with respect to centre, Memorial Sloan-Kettering Cancer
Centre (MSKCC) risk group (low–intermediate–high) and histo-
logical type (clear cell vs non-clear cell), the minimisation method
was applied using the Minim program (Evans et al, 2010, freely
available at: http://www-users.york.ac.uk/~mb55/guide/minim.htm,
last access: 14 September 2010). The program was set by the Unit
of Medical Statistics, Biometry and Bioinformatics. ITMO staffs
were involved in running the program and assigning eligible
patients to treatment arm.
Safety and efficacy assessments
Toxicity was assessed using the National Cancer Institute Common
Toxicity Criteria (NCI-CTC) (version 3.0). In the case of severe
toxicities (grades 3–4) that were deemed likely to be related to
sorafenib treatment, such as haematological toxicity, hypertension,
and skin reactions, sorafenib was reduced to a dose of 400mg once
daily or every other day, or was temporarily discontinued. If a
further dose reduction was required, or if no recovery (grades
0–1) was evident after a 2-week discontinuation of sorafenib,
treatment was discontinued. No dose reduction of IL-2 was
initially defined in the protocol; in the case of AEs related to IL-2:
drug administration was temporarily stopped and then restarted at
the same dosage after AE resolution. After the protocol amend-
ment, the occurrence of grade 3–4 AEs resulted in dose reduction
of IL-2 to 2 MIU on 5 days per week, 2 weeks on and 2 weeks off. If
after 2 weeks no recovery (grades 0–1) was observed, the patient
was withdrawn from the study.
RECIST criteria version 1.0 was used for response assessments.
Evaluations were carried out every 8 weeks during the first 24
weeks of treatment and then every 12 weeks thereafter. Tumour
measurements were carried out by CT or MRI scan, with all initial
diagnoses of complete and partial responses confirmed 4 weeks
later.
Statistical analysis
Sample size was calculated according to a phase 2.5 design (Simon
et al, 2001) considering PFS as endpoint (progression or death
without progression, whichever occurred first). Assuming expo-
nentially distributed time and 10% significance level (one-sided
log-rank test) to detect a 3-month increase in median PFS time in
the experimental arm from an anticipated median of 6 months in
the control arm (Escudier et al, 2009), 110 events yielded 80%
power to detect the target difference, with a sample size of 128
patients recruited over 24 months, and with a maximum length of
follow-up of 36 months.
The efficacy and safety analyses were performed on data from
the intent-to-treat population. All clinical and instrumental
variables and toxicity data were analysed by descriptive statistics:
mean, s.d., minimum, and maximum values for continuous
variables, and absolute and relative frequencies for categorical
variables. Curves relevant to PFS were estimated by the Kaplan–
Meier method and compared by means of the log-rank test.
Reports of AEs were categorised according to type, severity, and
outcome.
RESULTS
Patients
From October 2006 to February 2008, 128 patients entered the
study (66 receiving combination treatment with sorafenib plus
IL-2, and 62 receiving sorafenib monotherapy), all of whom were
included in the analyses. Four patients in both arms of treatment
were unevaluable for response because of refusal or being lost to
follow-up (Figure 1). Baseline characteristics of the two groups
were well balanced with regards to age, sex, histology, previous
surgery, tumour stage, site of metastatic disease, and risk category
(Table 1). Overall 73 and 74% of all patients in the combination
and single agent arms, respectively, were nephrectomised before
study entry. In total, 20 (30%) and 9 (15%) patients had only lung
disease in the combination and single agent arms, respectively,
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swhereas 31 (47%) and 32 (52%) patients had multiple sites of
disease in the combination and single agent arms, respectively.
Median duration of sorafenib alone or combination treatment
was 29 and 35 weeks, respectively.
Medical treatment was withdrawn in 15 and 12% of patients in
the combination and single agent arms, respectively, as a result of
treatment refusal, AEs, or being lost to follow-up. A dose reduction
was undertaken in 35 and 31% of patients in the combination and
monotherapy arms, respectively.
A dose reduction in the first cohort of patients receiving
sorafenib and higher dose of IL-2 was undertaken in 48% of the
population because of toxicity.
Efficacy
Median PFS was not significantly different between the two
treatment groups (P¼0.109): median PFS time was 33 weeks with
the combination of sorafenib plus IL-2, compared with 30 weeks
with sorafenib monotherapy. In all, 1- and 2-year PFS was 31.1%
(95% CI: 21.5–45.1) and 22.5% (95% CI: 14.1–35.9), respectively,
with combination therapy and 30.0% (95% CI: 20.2–44.6) and
11.3% (95% CI: 5.3–23.7) with sorafenib monotherapy (Figure 2).
With combination therapy, 18 patients (27.3%) had a partial
response and 35 (53.0%) had stable disease. Six patients (9.1%)
had a long-term partial response during at least 12 months. With
sorafenib monotherapy, 9 patients (14.5%) achieved partial
response and 37 (59.7%) had stable disease. The numbers of
patients with disease progression were 9 (13.6%) and 12 (19.4%) in
the combination and single arms, respectively. Tumour shrinkage
is illustrated in Figure 3. After a median follow-up time of 27
months, median OS was not reached in either treatment group.
The subgroup analysis demonstrated that improvement in PFS
was more evident in the population with low-risk disease than in
those with intermediate- or high-risk disease, with a median PFS of
47 weeks in the combination therapy group compared with 41
weeks in the sorafenib monotherapy group (Figure 4). In contrast,
in the population with intermediate-risk disease, median PFS was
21 weeks in the combination therapy group compared with 29
weeks in the sorafenib monotherapy group. PFS was not calculated
in the high-risk subgroup because of the low number of patients in
this category. Median PFS for patients with clear-cell histotype was
36 weeks with combination therapy and 32 weeks with sorafenib
Table 1 Patient characteristics at baseline (intent-to-treat population)
Sorafenib+IL-2
(n¼66)
Sorafenib
(n¼62)
Age at randomisation (years)
Median (interquartile range) 64 (57–69) 62 (52–69)
Gender, n (%)
Male 52 (79) 43 (69)
Female 14 (21) 19 (31)
Tumor stage at diagnosis, n (%)
I 5 (8) 3 (5)
II 17 (26) 10 (16)
III 14 (21) 24 (39)
IV 28 (42) 25 (40)
Missing 2 (3) 0
MSKCC risk group, n (%)
Low 36 (55) 34 (55)
Intermediate 27 (41) 24 (39)
High 3 (5) 4 (6)
Histological type, n (%)
Clear cell 58 (88) 56 (90)
Non-clear cell 8 (12) 6 (10)
Previous nephrectomy, n (%)
No 18 (27) 16 (26)
Yes 48 (73) 46 (74)
Sites of disease, n (%)
Lung 20 (30) 9 (15)
Liver 1 (2) 3 (5)
Lymph nodes 7 (11) 10 (16)
Kidney 1 (2) 1 (2)
Bone 2 (3) 3 (5)
Other site 4 (6) 4 (6)
Multiple sites 31 (47) 32 (52)
Abbreviations: IL-2¼interleukin 2; MSKCC¼Memorial Sloan Kettering Cancer
Centre.
Allocation
Follow-up
Analysis
Assessed for eligibility (n=131)
Randomised (n=128)
Enrolment
Allocated to S (n=62)
Excluded (n=3)
￿ Not meeting the inclusion criteria (n=2)
Allocated to S + IL-2 (n=66)
￿ S + higher-dose IL-2 (n=20)
￿ S + lower-dose IL-2 (n=46)
￿ Disease progression (n=50; 76%) ￿ Disease progression (n=49; 79%)
￿ Adverse events (n=6; 9%) ￿ Adverse events (n=4; 6%)
￿ Lost to follow-up and other (n=4; 6%) ￿ Lost to follow-up and other (n=4; 6%)
￿ Intent-to-treat population (n=66)
￿ Safety population (n=64)
Analysed (n=66)
￿ Intent-to-treat population (n=62)
￿ Safety population (n=64)
Analysed (n=62)
Discontinued study treatment (n=60; 91%)
Reason for discontinuation:
Discontinued study treatment (n=57; 92%)
Reason for discontinuation:
￿ Declined to participate (n=0)
￿ Other reasons (n=1)
Figure 1 Flow of patients through the study.
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Time (months)
Sorafenib + IL-2
Median PFS 33 weeks 30 weeks
31.1% (21.5–45.1%) 30.0% (20.2–44.6%)
22.5% (14.1–35.9%) 11.3% (5.3–23.7%)
12-month PFS
(95% CI)
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(95% CI)
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S
Figure 2 Progression-free survival curves in patients treated with the
combination of sorafenib plus IL-2 (SþIL2) or sorafenib alone (S).
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smonotherapy. The small number of patients with non-clear-cell
histotypes did not allow efficacy evaluations in these less frequent
histologies. Considering the two subgroups of patients receiving
the higher (full) or lower (reduced) doses of IL-2, median PFS was
43 weeks in the higher-dose subgroup and 31 weeks in the lower-
dose subgroup (Figure 5).
Considering those patients who had only lung metastases,
partial responses were observed in 5 out of 20 (25%) patients in the
combination therapy arm and 1 out of 9 (11%) patients in the
sorafenib arm. In this limited subgroup, tumour shrinkage was
overall documented in 10 out of 20 (50%) patients receiving
combination treatment.
Safety
The incidence of AEs in the sorafenib plus IL-2 combination
therapy group was 80% for any grade and 38% for grade X3 AEs.
In the sorafenib monotherapy group, 92% of patients reported AEs
of any grade and 25% reported grade X3 AEs. The most common
(incidence 45%) grade X3 AEs (combination vs monotherapy)
were: skin (14 vs 9%), gastrointestinal (8 vs 5%), and general
disorders (8 vs 3%). The overall AEs are shown in Table 2. For the
first 20 patients treated with higher-dose IL-2, the most common
AE requiring the protocol amendment was grade 42 asthenia,
which was reported in 11 patients (55%). After the amendment, the
incidence and manageability of these AEs improved. Dose
reduction due to AEs was undertaken in 22 patients (33%) in
the combination therapy group and in 15 patients (24%) in the
sorafenib monotherapy group.
DISCUSSION
Until recently, the prognosis of patients with mRCC was extremely
poor because of the high resistance of this disease to the available
therapeutic approaches, such as conventional cytotoxic che-
motherapy, radiotherapy, and hormone therapy. The subsequent
introduction of cytokines, particularly IL-2, produced varying
efficacy and safety outcomes, raising a series of questions about
the most appropriate doses and methods of administration. During
recent years, advances in the understanding of the molecular
biology of RCC have led to the successful development of several
new anti-angiogenic factors with promising efficacy and acceptable
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Figure 3 Waterfall plot showing the best variation from baseline in the sum of target lesion diameters. The investigator-assessed response is differentiated
by colour (partial response, white; stable disease, grey; disease progression, black).
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Figure 4 Progression-free survival curve in the low-risk subgroup of
patients treated with the combination of sorafenib plus IL-2 (SþIL2) or
sorafenib alone (S).
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higher-dose IL-2
Sorafenib +
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Median PFS 43 weeks 31 weeks 30 weeks
12-month PFS
(95% CI)
24-month PFS
(95% CI)
40.9% (24.8–67.6%) 25.7% (15.1–43.7%) 30.0% (20.2–44.6%)
22.9% (12.8–40.7%) 11.3% (5.3–23.7%) 22.7% (10.5–49.1%)
Figure 5 Progression-free survival curves in patients treated with the
combination of sorafenib plus higher dose of IL-2 (Sþhigher dose IL2),
sorafenib plus lower dose of IL-2 (Sþlower dose IL2), or sorafenib
alone (S).
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stoxicity profiles (Hudes et al, 2007; Escudier et al, 2007b; Motzer
et al, 2007, 2008; Rini et al, 2010; Sternberg et al, 2010). This has
resulted in a shift from the use of cytokine-based therapies to these
newer therapeutic approaches.
The current study is, to our knowledge, the first to evaluate the
combination of sorafenib and IL-2 in mRCC. When the study was
planned in 2006, there was limited knowledge regarding the
possible synergistic action of sorafenib plus IL-2. This trial was not
based on a previous phase I study or from any extrapolation from
preclinical data. Therefore, the timing and dose of drug admin-
istration, and IL-2 dose modifications were established on rather
empirical assumptions, chiefly based on concerns for safety of the
combination and without any specific guidance. Given that,
tolerability is difficult to interpret because of the heterogeneity
of IL-2 doses and schedules used.
The results of the present study failed to meet the pre-specified
statistical endpoints. The trend towards a superiority of the
combination treatment in terms of median PFS did not reach
statistical significance. The median PFS of 33 weeks observed in
patients treated with the combination compared with 30 weeks for
those treated with sorafenib alone (P¼0.109), does not appear to
support a synergistic effect of sorafenib and IL-2 in the overall
study population. The subgroup analysis demonstrated that the
difference in PFS was more evident in the population with low-risk
disease than in those with intermediate-risk disease, with a median
PFS of 47 weeks vs 41 weeks in favour of combination therapy.
These findings suggest that in some subgroups of patients with
slowly progressing disease, there may be a benefit to using
cytokines. In contrast, the population with intermediate-risk
disease had a median PFS of 21 vs 29 weeks in favour of sorafenib
monotherapy.
This analysis suggest a detrimental effect of the addition of IL-2 in
the population with intermediate prognostic features, consistent with
a previous study that showed that IL-2 treatment had no benefit in
patients with intermediate-risk disease (Negrier et al, 2007).
After treating the first 40 patients, a reduction in IL-2 dose to 3
MIU on 5 days per week, 2 weeks on followed by 2 weeks off, was
necessary because of the onset of high rates of asthenia (55% of
grade 3 or 4). The resulting median PFS was 43 weeks in patients
receiving the higher dose of IL-2 plus sorafenib vs 31 weeks in
patients who received the lower dose of IL-2 plus sorafenib,
suggesting that the efficacy of the combination treatment could be
associated with IL-2 dose. Therefore, assuming that a synergistic
effect could be recognised, factors such as route of administration,
schedule, and doses of IL-2 used could be called into question as
responsible for the different results. Previous investigations of IL-2
have shown that by changing the schedule of the drug by either
continuous infusion or subcutaneous administration it is possible
to decrease toxicity while maintaining therapeutic efficacy. More-
over, comparisons between higher and lower doses of IL-2 have
shown a higher response rate with higher doses without, however,
any significant survival advantage (Negrier et al, 1998). In contrast,
in selected patients, the use of high doses of IL-2 has provided
long-term complete remission (Rosenberg et al, 1994).
By contrast, results from the AVOREN study demonstrated that
a dose reduction of IFN-a did not influence the activity of the
combination of bevacizumab plus IFN-a when administered as
first-line treatment in mRCC (Melichar et al, 2008). Previous
experience suggests that the activity of IL-2 could be also related to
the site of disease (Akaza et al, 2006). Proof that lung metastases
had more benefit from low-dose IL-2 in comparison with others
sites of disease (Miyake et al, 2009). In our trial, 5 out of 20 (25%)
patients who had only lung disease developed a partial response
with the combination therapy, while 1 out of 9 (12%) patients in
the sorafenib arm had a partial response. The limited number of
patients with these characteristics means that we cannot draw any
firm conclusions concerning the usefulness of the combination of
sorafenib and IL-2 in patients with only lung disease. Similar to
other trials combining sorafenib±IFN-a, the current results
support the hypothesis that immunotherapy does not add much
to sorafenib as first-line therapy (Gollob et al, 2007; Ryan et al,
2007; Bracarda et al, 2008; Jonasch et al, 2010). In addition, the
combination of sunitinib and IFN-a was studied in a phase I trial
and showed no evidence of a therapeutic synergistic effect and
displayed a poor safety profile (Motzer et al, 2009).
In conclusion, in the present study, the combination of
sorafenib plus IL-2 did not improve the clinical efficacy of
sorafenib monotherapy as first-line treatment of mRCC. Subgroup
analysis suggested that patients with clear-cell histology and those
with good prognosis receiving higher doses of IL-2 may respond
best to the combination therapy.
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Table 2 Adverse events (X5% in either treatment group)
Sorafenib+IL-2
(n¼66)
Sorafenib
(n¼62)
Adverse event
Any
grade
Grade
X3
Any
grade
Grade
X3
Fatigue, n (%) 12 (19) 2 (3) 10 (16) 1 (2)
Chest Pain, n (%) 3 (5%) 1 (2) 0 0
Influenza-like illness, n (%) 8 (12) (2) 0 0
Pyrexia, n (%) 13 (20) 0 1 (2) 0
Anemia, n (%) 3 (5) 0 5 (8) 0
Neutropenia, n (%) 4 (6) 1 (2) 0 0
Hypertension, n (%) 6 (9) 1 (2) 10 (16) 4 (6)
Diarrhea, n (%) 15 (23) 0 17 (27) 0
Hemorrhoids, n (%) 1 (2) 0 4 (6) 0
Stomatitis, n (%) 16 (24) 3 (5) 7 (11) 1 (2)
Nausea, n (%) 3 (5) 0 3 (5) 1 (2)
Hand–foot skin reaction, n (%) 27 (41) 8 (12) 32 (52) 6 (10)
Alopecia, n (%) 4 (6) 0 4 (6) 0
Pruritus, n (%) 3 (5) 0 4 (6) 0
Piastrinopenia, n (%) 2 (3) 0 4 (6) 0
Anorexia, n (%) 3 (5) 0 1 (2) 0
Hypophosphatemia, n (%) 4 (6) 1 (2) 3 (5) 0
Blood amylase increase, n (%) 1 (2) 0 3 (5) 0
Blood creatinine increased, n (%) 1 (2) 0 3 (5) 0
Transaminase increase, n (%) 0 0 3 (5) 1 (2)
Hyperuricemia, n (%) 4 (6) 0 6 (10) 0
Arthralgia, n (%) 5 (8) 0 0 0
Dyspnoea, n (%) 5 (8) 0 1 (2) 1 (2)
Abbreviation: IL-2¼interleukin 2.
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